Sign in

    Bubalan Pachayapan

    Managing Director and Senior Biotech Analyst at ROTH Capital

    Boobalan Pachaiyappan, Ph.D., is a Managing Director and Senior Biotech Analyst at Roth Capital Partners, specializing in coverage of biotechnology companies such as Cervomed, PolyPid, Verona Pharma, and Cingulate. Over his equity research career, he has issued approximately 138 ratings, with a success rate of 29% and an average return per rating of -12.3% over a one-year holding period, as tracked by TipRanks. Pachaiyappan began his post-Ph.D. professional journey around 2011, has roughly five years of sell-side analyst experience, and joined Roth after previous roles such as equity research analyst at H.C. Wainwright & Co. He holds a FINRA registration (CRD#: 7149624), a Ph.D. in Medicinal Chemistry from the University of Illinois at Chicago, and an M.S. in Chemistry from Virginia Tech.

    Bubalan Pachayapan's questions to CAPRICOR THERAPEUTICS (CAPR) leadership

    Bubalan Pachayapan's questions to CAPRICOR THERAPEUTICS (CAPR) leadership • Q2 2025

    Question

    An analyst dialing in for Bubalan Pachayapan asked if the Type A meeting is an opportunity for FDA clarification or a bellwether for a future resubmission, and also questioned the value of the mid-cycle review process given the CRL outcome.

    Answer

    CEO Linda Marbán stated that Capricor will share information from the meeting as it becomes available. Regarding the review process, she commented that in their experience, a successful mid-cycle review was not predictive of the final BLA outcome. She also noted that the company's current focus is on U.S. approval before advancing ex-U.S. strategies.

    Ask Fintool Equity Research AI